chronic myelomonocytic leukemia

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:myelodysplastic/myeloproliferative_neoplasm leukemia
gptkbp:abbreviation	gptkb:CMML
gptkbp:affects	blood bone marrow
gptkbp:canProgressTo	gptkb:acute_myeloid_leukemia
gptkbp:characterizedBy	dysplasia in one or more myeloid lineages increased myeloblasts persistent monocytosis
gptkbp:commonIn	males
gptkbp:diagnosedBy	blood test bone marrow biopsy
gptkbp:differentialDiagnosis	gptkb:chronic_myeloid_leukemia other myelodysplastic syndromes reactive monocytosis
gptkbp:firstDescribed	1976
gptkbp:hasBlastsPercentage	<20% in blood and marrow
gptkbp:hasMonocyteCount	>1x10^9/L
gptkbp:hasPrognosticScoringSystem	gptkb:CPSS gptkb:MDAPS
https://www.w3.org/2000/01/rdf-schema#label	chronic myelomonocytic leukemia
gptkbp:ICD-10_code	C93.1
gptkbp:incidence	rare 0.3 per 100,000 per year
gptkbp:medianAge	65-75 years
gptkbp:mutationAssociatedWith	gptkb:JAK2 gptkb:CBL gptkb:KRAS gptkb:NRAS gptkb:ASXL1 gptkb:SETBP1 gptkb:SRSF2 gptkb:TET2 gptkb:RUNX1
gptkbp:prognosis	variable often poor
gptkbp:riskFactor	older age exposure to chemicals male gender
gptkbp:subspecies	gptkb:CMML-1 gptkb:CMML-2
gptkbp:symptom	gptkb:anemia fever fatigue splenomegaly weight loss
gptkbp:treatment	chemotherapy stem cell transplantation hypomethylating agents
gptkbp:WHOClassification	gptkb:myelodysplastic/myeloproliferative_neoplasm
gptkbp:bfsParent	gptkb:PDGFR gptkb:PDGFRB
gptkbp:bfsLayer	6